Insulin and Blood Sugar in Athletes: Managing Glucose Across Sport, Age, and Special Populations

How Exercise Changes Insulin Signaling at the Cellular Level

Skeletal muscle can pull glucose out of the bloodstream during physical activity through a pathway that does not require insulin at all. Contracting muscle fibers activate AMP-activated protein kinase (AMPK) and release calcium, both of which drive GLUT4 transporter vesicles to the cell surface. This mechanism operates in parallel with the insulin-stimulated pathway and explains why blood glucose falls during aerobic exercise even when circulating insulin levels are low [1].

The effect persists well beyond the workout. A single bout of moderate aerobic exercise increases whole-body insulin sensitivity for 24 to 48 hours, primarily through enhanced GLUT4 expression and improved mitochondrial oxidative capacity [2]. For athletes with type 2 diabetes, this window is one of the most powerful non-pharmacological tools available to reduce fasting and postprandial glucose.

Anaerobic and high-intensity interval efforts tell a different story. A sprint or heavy resistance set triggers a sharp catecholamine surge that stimulates hepatic glucose output and can push blood glucose up by 40 to 80 mg/dL within minutes [3]. This transient hyperglycemia typically resolves within 60 to 90 minutes, but athletes with type 1 diabetes who stack rapid-acting insulin on top of this rise may overcorrect and experience late hypoglycemia.

The practical implication is that sport type determines the direction of the glycemic response. Endurance athletes face a falling glucose curve; power athletes often face a rising one first and a falling one later.

Pre-Exercise Glucose Targets and Insulin Dose Adjustments

The 2024 American Diabetes Association Standards of Care recommend that adults with type 1 diabetes begin aerobic exercise with a glucose level of 126-180 mg/dL [4]. Targets below 90 mg/dL warrant 15-30 g of fast-acting carbohydrate before starting. Targets above 250 mg/dL with confirmed ketosis mean the session should be postponed.

For prandial insulin, a commonly used adjustment is a 25-75% dose reduction for the meal immediately before aerobic exercise lasting more than 45 minutes. The exact reduction depends on exercise intensity, duration, and the individual's insulin-to-carbohydrate ratio. A 2013 randomized crossover study by Rabasa-Lhoret et al. (N=20) found that a 75% reduction in pre-exercise rapid-acting insulin, combined with 15 g carbohydrate, reduced exercise-induced hypoglycemia incidence from 50% to 10% during 45-minute moderate cycling [5].

Pump users have an additional lever: suspending or reducing the basal rate. Most protocols recommend reducing basal insulin by 50-80% starting 60-90 minutes before aerobic exercise. Waiting until exercise begins is less effective because subcutaneous insulin absorption is already underway [6].

A straightforward decision framework for dose adjustments:

1. Identify sport type: aerobic dominant (reduce pre-meal insulin 25-75%), anaerobic dominant (consider a modest reduction of 10-25% or no reduction), or mixed (reduce 25-50% and plan for post-exercise correction).
2. Check glucose 30 minutes before, at exercise start, and every 30-45 minutes during sessions longer than 60 minutes.
3. Keep fast-acting carbohydrate within reach throughout any session. Dextrose tablets (15 g) are preferred over gels with fructose for predictable absorption speed.
4. After exercise, reduce overnight basal or set a pump temporary basal rate at 70-80% of normal for 6-8 hours if the session was prolonged, because nocturnal hypoglycemia risk peaks in this window.

Managing Hypoglycemia Risk During and After Training

Hypoglycemia during exercise is the primary safety concern for insulin-using athletes. Symptoms such as tremor, confusion, and diaphoresis may be masked by normal exercise-related sweating and cardiovascular effort, making recognition harder in a training environment [7].

The 15-15 rule (15 g glucose, recheck in 15 minutes) remains the standard first-line treatment for mild-to-moderate hypoglycemia. Glucagon is the rescue option. Nasal glucagon (Baqsimi 3 mg) or injectable glucagon 1 mg IM/SC should be accessible at any training facility where athletes with type 1 diabetes train. A 2021 study published in Diabetes Care found that 4 mg intranasal glucagon resolved exercise-associated hypoglycemia in 100% of participants within 30 minutes, with no need for IV dextrose [8].

Nocturnal hypoglycemia is a delayed risk. A 2009 study by Tsalikian et al. in type 1 diabetes found that afternoon exercise at moderate intensity raised the overnight hypoglycemia rate from 7% on rest days to 42% after exercise days, even when bedtime glucose appeared adequate [9]. Athletes should consider a 15-30 g slow-digesting carbohydrate snack before sleep after heavy training days.

Continuous glucose monitoring reduces but does not eliminate this risk. The Dexcom G7 and FreeStyle Libre 3 both carry an approximately 5-minute lag between interstitial and blood glucose, which matters during rapid glucose swings. During intense sweating, adhesion and signal quality may also degrade, making fingerstick confirmation advisable for treatment decisions.

Insulin and Blood Sugar Management in Pregnant Athletes

Exercise during pregnancy with gestational diabetes mellitus (GDM) or pre-existing diabetes requires a distinct approach. The American College of Obstetricians and Gynecologists (ACOG) states that "physical activity during pregnancy benefits most women and is associated with a reduced risk of excessive gestational weight gain, gestational diabetes, preterm birth, and cesarean delivery" [10]. For women with GDM, 30 minutes of moderate exercise five times per week is first-line management before insulin is added.

When insulin is required, total daily doses in active pregnant women with GDM may be 10-25% lower than in sedentary counterparts. Pregnancy itself raises insulin resistance progressively through the second and third trimesters due to placental lactogen, cortisol, and progesterone. Exercise counteracts this resistance through the same GLUT4-mediated mechanisms seen in non-pregnant athletes [11].

Specific safety considerations for pregnant athletes:

• Avoid supine exercise after the first trimester; impaired vena cava return drops cardiac output and reduces uteroplacental perfusion.
• Target glucose during exercise: 70-140 mg/dL. Fetal heart rate monitoring is not required for routine moderate aerobic exercise, but glucose must remain in range.
• Hypoglycemia treatment with 15 g glucose applies the same way; glucagon is considered safe in pregnancy based on animal data, though controlled human trials are limited.
• Contact sports and activities with fall risk are contraindicated after 12 weeks.

Insulin and Blood Sugar in Child and Adolescent Athletes

Children with type 1 diabetes face compounding variability: smaller total insulin doses mean any adjustment has a proportionally larger effect, growth hormone levels are higher and more erratic, and the physical demands of youth sports are less predictable than adult training schedules.

A key clinical reference is the ISPAD 2022 Clinical Practice Consensus Guidelines, which state that "insulin dose reductions and carbohydrate supplementation are the cornerstones of managing exercise in children with type 1 diabetes, and continuous glucose monitoring with alerts set at 126 mg/dL is recommended during sport" [12].

Practical adjustments for pediatric athletes:

• Pre-exercise glucose target: 126-180 mg/dL, the same as adults, but the lower acceptable limit before exercise should be set at 100 mg/dL given faster glucose consumption rates in children.
• Rapid-acting insulin before sports meals: reduce by 25-50%. Younger children (under 10) often need the larger end of this reduction.
• Carbohydrate supplementation during exercise: 0.5-1.0 g/kg per hour during moderate aerobic exercise. A 30 kg child needs approximately 15-30 g per hour.
• Nocturnal hypoglycemia is the primary risk. Parents and coaches should check glucose at 2 AM after any afternoon or evening athletic session.

Hybrid closed-loop systems such as the Tandem Control-IQ or Medtronic MiniMed 780G have been shown to significantly reduce overnight hypoglycemia in pediatric athletes. A 2022 trial (N=108 children aged 6-13) published in the New England Journal of Medicine found that hybrid closed-loop control reduced time below 70 mg/dL from 4.1% to 1.6% over six months compared with sensor-augmented pump therapy (P<0.001) [13].

Insulin and Blood Sugar in Older Adult Athletes

Masters athletes and older adults with diabetes represent a growing population. Sarcopenia, reduced renal clearance, polypharmacy, and impaired hypoglycemia awareness all compound glycemic risk in this group.

Insulin clearance slows with age. Glomerular filtration rate (GFR) declines at roughly 1 mL/min per year after age 40, meaning even athletes with no formal renal diagnosis may have modestly prolonged insulin half-lives by their sixties [14]. This matters because a pre-exercise dose calculated for a 45-minute workout may still be active two hours later in a 65-year-old runner.

Hypoglycemia unawareness is more common in older adults, partly due to blunted autonomic responses. The clinical threshold for aggressive glucose lowering in older athletes should be higher: the ADA 2024 Standards recommend an A1C target of 7.0-8.0% for older adults with hypoglycemia unawareness or limited life expectancy, compared with the typical target of <7.0% [4].

Exercise prescription itself remains beneficial. A meta-analysis in Diabetes Care (2016, N=8,538 participants across 23 trials) found that structured exercise reduced A1C by a mean of 0.67 percentage points in older adults with type 2 diabetes, a reduction comparable to adding a second oral agent [15]. Resistance training twice per week combined with aerobic activity three to five times per week produced the greatest glycemic benefit in this population.

Practical adjustments for older athletes:

• Use longer glucose monitoring windows (check at 30, 60, and 90 minutes post-exercise) because glucose nadir may be delayed.
• Prefer basal insulin analogs (glargine U-300, degludec U-200) over NPH in active older adults; flat pharmacokinetic profiles reduce peak-dose hypoglycemia risk.
• Review all concomitant medications: beta-blockers blunt tachycardia as a hypoglycemia warning sign; sulfonylureas add independent hypoglycemia risk.

Insulin and Blood Sugar in Athletes with Renal Disease

Chronic kidney disease (CKD) profoundly alters insulin pharmacokinetics. The kidneys contribute roughly 30-40% of total insulin degradation. As GFR falls below 60 mL/min/1.73m2 (CKD stage 3), insulin half-life extends and total daily insulin requirements typically fall. By CKD stage 5, patients may require 25-50% less insulin than at diagnosis [16].

For athletes with CKD who continue competitive or recreational training:

• Severe hypoglycemia risk is up to 5 times higher than in athletes with normal renal function. This figure comes from a UK Biobank observational analysis (N=19,309 adults with diabetes) that found CKD was independently associated with a hazard ratio of 4.9 for severe hypoglycemia after multivariable adjustment [17].
• Pre-exercise glucose targets should be set slightly higher: 140-180 mg/dL rather than 126-180 mg/dL, given the extended tail of insulin action.
• Metformin is contraindicated at GFR <30 mL/min/1.73m2 (eGFR <30). Athletes on this drug should confirm their eGFR is above this threshold before continuing.
• SGLT2 inhibitors (empagliflozin, dapagliflozin) carry an FDA warning regarding diabetic ketoacidosis, and their glycosuric effect may be attenuated at GFR <45. Use with caution and ensure adequate hydration in athletes prone to sweat-related volume depletion [18].
• Erythropoietin-stimulating agents used in some CKD patients improve oxygen-carrying capacity and exercise performance, but they do not alter glycemic risk directly.

Dialysis patients who exercise face additional complexity: glucose is lost in dialysate during hemodialysis sessions, so insulin timing relative to dialysis must be individualized. A standard approach is to withhold the pre-dialysis rapid-acting insulin dose and check glucose every 30 minutes during the session.

Continuous Glucose Monitoring and Technology for Athletic Use

CGM has shifted glucose management from reactive to proactive for active patients. Current options include the Dexcom G7 (10-day wear, 5-minute update interval, approved for non-adjunctive use) and FreeStyle Libre 3 (14-day wear, 1-minute update interval, real-time alerts).

For athletes, device-specific considerations matter:

• Both devices use interstitial fluid, not blood. During rapid glucose changes (dropping faster than 2 mg/dL per minute during vigorous aerobic exercise), interstitial readings may underestimate true blood glucose by 15-25 mg/dL [19].
• Adhesive failure due to sweat is a real problem. Overtape products (Skin Tac, Tegaderm) extend wearability during water sports or heavy sweating conditions.
• Alarm fatigue is a documented issue in competitive athletes. Setting low glucose alerts at 90 mg/dL (rather than 70 mg/dL) gives a wider action window before true hypoglycemia occurs.

Closed-loop insulin delivery systems, when paired with CGM, represent the current best available technology for managing exercise-related glycemic variability. The iLet Bionic Pancreas (approved by FDA in 2023) uses a fully automated insulin-only algorithm that adjusts delivery every five minutes without user carbohydrate counting, and a key trial (N=440) showed time-in-range improvement from 51% to 73% over 13 weeks compared with standard insulin delivery [20].

Drug Reference: Rapid-Acting Insulins Commonly Used by Athletes

Understanding the pharmacokinetics of available rapid-acting insulins is necessary for precise exercise timing:

• Insulin lispro (Humalog, Admelog): onset 15 minutes, peak 30-90 minutes, duration 3-5 hours.
• Insulin aspart (NovoLog, Fiasp): Fiasp has a faster onset (9-11 minutes) and earlier peak, which may be advantageous for post-exercise correction doses but requires careful timing to avoid hypoglycemia during late-rising post-anaerobic glucose.
• Insulin glulisine (Apidra): onset 10-15 minutes, peak 30-90 minutes, duration 3-5 hours; similar to lispro.
• Ultra-rapid lispro (Lyumjev): onset approximately 11 minutes; FDA-approved 2020; may reduce post-meal glucose excursions more effectively but increases early hypoglycemia risk if exercise starts within 60 minutes of dosing.

For athletes who train within two hours of meals, Fiasp or Lyumjev require extra caution. The faster peak means hypoglycemia may coincide with the glucose-lowering effect of exercise itself [21].